Germany's Q1 2026 Medical Cannabis Imports Hit 50,539 kg as Canada Supplies 53%

Germany imported 50,539 kilograms of medical cannabis in the first quarter of 2026, according to figures published by the Federal Institute for Drugs and Medical Devices (BfArM) — and Canadian producers supplied more than half of it. The Germany cannabis imports data, first reported by StratCann and Hemp Gazette on May 21, 2026, confirms what international market analysts have argued for two years: Germany has become the indispensable European destination for licensed medical cannabis, and Canada has become its indispensable supplier.

The number is significant in both directions. Imports were down roughly 15 percent from the record fourth quarter of 2025, when BfArM reported just over 59,000 kilograms of medical cannabis crossing into the country. But Q1 2026 imports were up about 34 percent year-over-year compared with Q1 2025, suggesting that Germany's post-CanG (Cannabis Act) demand surge has settled into a higher, structurally elevated baseline rather than the explosive early-quarter spikes that characterized 2024 and early 2025.

The Country Breakdown

Canada led the field with 26,753 kg in Q1 2026 shipments to Germany — about 53 percent of total imports. Portugal came second with 10,342 kg, often serving as a regional intermediary that ships cannabis cultivated in or routed through the Iberian Peninsula. Denmark followed with 3,338 kg. The remaining roughly 10,000 kg came from a mix of smaller supplier countries including the Netherlands, Israel, Spain, Macedonia, and several emerging African cultivation jurisdictions.

What makes the Canadian figure remarkable is how recently Canada was just one player in a fragmented European supply chain. As recently as 2022, Canada accounted for roughly 30 percent of Germany's medical cannabis imports, with Portugal, Denmark, and the Netherlands collectively supplying the majority. The reversal reflects two structural advantages Canadian producers have built over the last five years: scaled EU-GMP-certified facilities and consistent cultivar approval through BfArM's review process.

EU-GMP certification — short for European Good Manufacturing Practices — is the regulatory linchpin of the European medical cannabis market. To ship cannabis flower or extracts into Germany, France, Italy, or any EU pharmacy-distributed market, producers must operate facilities that meet pharmaceutical-grade quality standards typically associated with prescription drug manufacturing. Building a EU-GMP facility costs tens of millions of dollars and can take 18 to 36 months to commission. Canada's largest licensed producers — Aurora, Tilray, Canopy Growth, and a tier of mid-size operators including Decibel, Avant Brands, and Auxly — invested early and have been steadily expanding capacity.

Why Q1 Imports Slowed From Q4

The 15 percent quarter-over-quarter drop is not, despite some headlines, evidence that the German market is cooling. The pattern reflects a combination of seasonal demand factors, inventory cycles among German pharmacies, and BfArM's increasingly active scrutiny of incoming cannabis cultivars. In late 2025, BfArM clarified its cultivar approval process amid heightened EU-GMP scrutiny, and several shipments were delayed pending updated documentation. Industry sources have indicated that the Q1 dip likely included some normalized inventory drawdown after pharmacy stockpiling ahead of CanG-related regulatory uncertainty.

More telling is the year-over-year comparison. Q1 2026's 50,539 kg compares to roughly 37,700 kg in Q1 2025 — a 34 percent increase. That sustained year-over-year growth, even from an already-elevated 2025 baseline, suggests that the German market is continuing to absorb more medical cannabis as patient counts grow and as the German telehealth model — which allows physicians to prescribe medical cannabis via remote consultation — continues to expand patient access. Industry estimates put Germany's active medical cannabis patient population at somewhere between 500,000 and 1 million as of early 2026, depending on how the count is constructed.

What This Means for Canadian Producers

For Canadian licensed producers, the Q1 2026 figures provide hard validation of an export-focused strategy that many in the industry had begun to question. The domestic Canadian recreational market remains brutally competitive, with wholesale flower prices that have compressed continuously since 2019 and provincial distributor markups that squeeze producer margins. Canadian recreational producers have increasingly looked to international medical markets — and Germany in particular — as the place where their EU-GMP-certified output commands premium pricing.

The numbers behind that strategic shift are striking. Wholesale Canadian recreational dried flower trades for roughly CAD $1.50–$2.50 per gram, depending on potency, format, and region. Exported EU-GMP medical flower to Germany routinely sells for €5–€8 per gram, or roughly CAD $7–$11 — a 4–6x markup. Even after EU-GMP compliance costs, regulatory overhead, and logistics, the gross margins on German exports are substantially higher than what most producers can earn at home.

That dynamic has accelerated consolidation among Canadian licensed producers. The companies with EU-GMP capacity have become acquisition targets, and smaller domestic-focused producers have either pursued EU-GMP certification themselves or partnered with established exporters to access the German market through licensing or supply agreements.

What This Means for the European Market

The Germany cannabis imports figures also reshape the competitive landscape across Europe. Germany is by far the largest European medical cannabis market, but it is no longer alone. France, after years of stalled pilot programs, launched a broader medical cannabis framework in late 2025. The Czech Republic continues to expand. Italy's medical cannabis program has grown steadily. Spain, Poland, and Switzerland are all watching German implementation closely as they consider their own next moves.

Canadian dominance in Germany positions Canadian producers to play a similar role in any of these emerging markets, provided EU-GMP infrastructure can keep pace. The risk for Canadian dominance is twofold. First, Portugal — already the second-largest supplier to Germany — has expanded cultivation capacity aggressively and may pursue greater market share. Second, several African nations (Lesotho, Uganda, Malawi, Zimbabwe) have invested in cannabis cultivation with explicit ambitions to supply European pharmaceutical markets at lower production costs than Canadian producers can match.

For now, though, the Canadian advantage looks durable. EU-GMP certification is a meaningful moat, and the four-to-six-year head start Canadian producers built over emerging-market competitors is not easily closed.

What Could Shift the Trajectory

Three developments could reshape the Q1 2026 picture in 2027 and beyond. First, the U.S. Schedule III rescheduling, finalized in April 2026 and now in implementation, opens the long-term possibility of U.S. producers entering international markets — though federal interstate-commerce restrictions on cannabis would have to evolve significantly before that becomes practical. Second, Germany's own domestic cultivation framework continues to expand, and German-grown medical cannabis may capture share that currently goes to imports. Third, European market consolidation may produce regional players large enough to challenge Canadian production dominance.

But these are 2027–2030 questions. For Q1 2026, the data tell a clear story: Germany continues to grow as the anchor European medical market, and Canada continues to supply more than half of what crosses its border.

Key Takeaways

• Germany imported 50,539 kg of medical cannabis in Q1 2026 — up 34% year-over-year, down 15% from a record Q4 2025.
• Canada supplied 26,753 kg (53% of total imports); Portugal supplied 10,342 kg (20%); Denmark supplied 3,338 kg (7%).
• EU-GMP-certified Canadian producers earn 4–6x premiums on German exports compared with domestic Canadian recreational flower.
• BfArM's stricter cultivar review process and pharmacy inventory cycles drove the Q1 quarter-over-quarter decline.
• Germany's 500K–1M active medical patient base continues to underpin sustained year-over-year import growth.

Explore cannabis news, find dispensaries, and join the community at Budpedia.